Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 24Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 12Urinary Bladder Neoplasms 6Sarcoma 6Prostatic Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5Kidney Neoplasms 5Ovarian Neoplasms 4Glioblastoma 4Carcinoma, Transitional Cell 4Uveal Melanoma 3Small Cell Lung Carcinoma 3Myelodysplastic Syndromes 3Mesothelioma 3Histiocytoma, Malignant Fibrous 3Colorectal Neoplasms 3Chordoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 3Nivolumab 3Biopsy 2dehydroftorafur 1X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mitozytrex 1Mitomycin 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Colonoscopy 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anal Canal Carcinoma × Ipilimumab × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡